Chronic hepatitis B market seen reaching $4.74B by 2030
The Business Research Company projects the chronic hepatitis B market will rise from $3.93 billion in 2025 to $4.74 billion by 2030, driven by screening, antiviral use and next-generation HBV therapies. North America held the largest share in 2025 as global vaccination gaps and persistent infection rates continue to support demand.
Why it matters: - Chronic hepatitis B is a long-term infection that can lead to liver damage, failure or cancer. - The market outlook signals sustained demand for testing, treatment and long-term monitoring as HBV remains a major global disease burden. - Faster diagnosis, better access to antivirals and new therapy approaches could change how patients are treated over the next several years.
What happened: - The Business Research Company released its Chronic Hepatitis B Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the chronic hepatitis B market will grow from $3.93 billion in 2025 to $4.1 billion in 2026. - The report forecasts the market will reach $4.74 billion by 2030. - The company projects a 4.2% CAGR for the historical period and a 3.7% CAGR through 2030. - North America held the largest share of the chronic hepatitis B market in 2025.
The details: - Chronic hepatitis B is a persistent hepatitis B virus infection lasting longer than six months. - The condition can remain symptomless for years. - Blood testing can diagnose chronic hepatitis B. - Antiviral drugs and regular health monitoring are used to manage the disease. - Historical market growth was driven by hepatitis B screening, broader access to antiviral medications, greater awareness of liver disease complications, wider use of nucleos(t)ide analogs and long-term disease monitoring protocols. - The forecast period is supported by investment in next-generation HBV therapies, shorter treatment regimens, therapeutic vaccine development and efforts to eliminate viral reservoirs. - Additional expected trends include long-term antiviral use, functional cure strategies, early detection and disease monitoring, immune-modulating therapies and patient adherence initiatives. - Low vaccination coverage in many low- and middle-income countries keeps transmission rates elevated. - Higher infection rates increase demand for diagnostic testing and treatment solutions. - A CDC report in June 2024 said raising global hepatitis B vaccination coverage to 90% and treatment availability to 80% could prevent 26 million new infections and save 9 million lives between 2022 and 2050. - The CDC also reported 1.2 million new HBV infections in 2022. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis.
Between the lines: - The market is growing, but the pace is moderate rather than explosive. - The report points to a shift from broad antiviral management toward more targeted and potentially curative treatment approaches. - Persistent vaccination gaps suggest the burden of chronic hepatitis B will remain tied to public health access, not just drug innovation.
What's next: - Drug developers and public health agencies will likely continue focusing on shorter regimens, functional cures and better adherence. - Demand should remain strong in markets where vaccination coverage and treatment access lag. - Regional growth will likely depend on screening rates, therapy availability and how quickly new HBV treatments reach patients.
The bottom line: - Chronic hepatitis B remains a large, steady market shaped by ongoing infection risk, treatment innovation and uneven global access to prevention and care.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Middle East News Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.